Janet Huffman

Chief Financial Officer, Chief Executive Officer (Principal Accounting and Financial Officer), Oragenics, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

Janet Huffman signed the annual report of Oragenics, Inc. on Form 10-K as Chief Financial Officer, Chief Executive Officer (Principal Accounting and Financial Officer), filed March 16, 2026.¹ A later filing by Oragenics, Inc., made on July 6, 2026, names John Spencer as its chief financial officer; the record holds no filing that reports the end of Janet Huffman's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Oragenics, Inc. (OGEN) Pharmaceutical Preparations	Chief Financial Officer, Chief Executive Officer (Principal Accounting and Financial Officer)	A later filing names a successor John Spencer, filed July 6, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 16, 202610-K filed
Janet Huffman signed the annual report of Oragenics, Inc. on Form 10-K as Chief Financial Officer, Chief Executive Officer (Principal Accounting and Financial Officer), filed March 16, 2026.
/s/ Janet Huffman Chief Financial Officer, Chief Executive Officer March 16, 2026 Janet Huffman (Principal Accounting and Financial Officer)
[1] Annual report on Form 10-K by Oragenics, Inc., filed with the SEC on March 16, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Oragenics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 16, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Janet Huffman wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.